Novo Nordisk A/S (NYSE:NVO) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 33.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 146,866 shares of the company’s stock after selling 73,753 shares during the quarter. Calamos Advisors LLC’s holdings in Novo Nordisk A/S were worth $12,633,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd bought a new stake in Novo Nordisk A/S in the third quarter valued at about $98,765,000. DAVENPORT & Co LLC lifted its holdings in shares of Novo Nordisk A/S by 75.1% in the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after purchasing an additional 451,641 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at approximately $42,017,000. Finally, World Investment Advisors LLC boosted its position in shares of Novo Nordisk A/S by 2,655.9% during the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after purchasing an additional 270,234 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $82.64 on Tuesday. The company has a market capitalization of $370.85 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 0.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The stock has a 50-day moving average of $93.56 and a 200 day moving average of $112.87.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NVO shares. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.